NASDAQ:TECH Bio-Techne - TECH Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Bio-Techne Co. Please log in to your account or sign up in order to add this asset to your watchlist. $79.16 -1.69 (-2.09%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$77.66▼$80.0850-Day Range$78.68▼$327.0752-Week Range$68.00▼$113.81Volume1.25 million shsAverage Volume1.11 million shsMarket Capitalization$12.43 billionP/E Ratio49.17Dividend Yield0.40%Price Target$104.45 ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Bio-Techne MarketRank™ ForecastAnalyst RatingModerate Buy2.78 Rating ScoreUpside/Downside32.0% Upside$104.45 Price TargetShort InterestHealthy1.45% of Shares Sold ShortDividend StrengthWeakBased on Four FactorsSustainability-1.41Upright™ Environmental ScoreNews Sentiment0.25Based on 17 Articles This WeekInsider TradingSelling Shares$65,608 Sold Last QuarterProj. Earnings Growth21.43%From $1.82 to $2.21 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.3.28 out of 5 starsMedical Sector8th out of 1,025 stocksBiological Products, Except Diagnostic Industry1st out of 168 stocks 4.4 Analyst's Opinion Consensus RatingBio-Techne has received a consensus rating of Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $104.45, Bio-Techne has a forecasted upside of 32.0% from its current price of $79.16.Amount of Analyst CoverageBio-Techne has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.45% of the outstanding shares of Bio-Techne have been sold short.Short Interest Ratio / Days to CoverBio-Techne has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bio-Techne has recently decreased by 3.39%, indicating that investor sentiment is improving. Previous Next 1.7 Dividend Strength Dividend YieldBio-Techne has a dividend yield of 0.40%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthBio-Techne has only been increasing its dividend for 1 years.Dividend CoverageThe dividend payout ratio of Bio-Techne is 19.88%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Bio-Techne will have a dividend payout ratio of 14.48% next year. This indicates that Bio-Techne will be able to sustain or increase its dividend. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBio-Techne has received a 69.12% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antibodies", "Biochemical assay kits", and "Laboratory reagents" products. See details.Environmental SustainabilityThe Environmental Impact score for Bio-Techne is -1.41. Previous Next 2.4 News and Social Media Coverage News SentimentBio-Techne has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Bio-Techne this week, compared to 4 articles on an average week.Search InterestOnly 7 people have searched for TECH on MarketBeat in the last 30 days. This is a decrease of -30% compared to the previous 30 days.MarketBeat Follows2 people have added Bio-Techne to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bio-Techne insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $65,608.00 in company stock.Percentage Held by InsidersOnly 4.45% of the stock of Bio-Techne is held by insiders.Percentage Held by InstitutionsOnly 23.92% of the stock of Bio-Techne is held by institutions. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Bio-Techne are expected to grow by 21.43% in the coming year, from $1.82 to $2.21 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bio-Techne is 49.17, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 130.69.Price to Earnings Ratio vs. SectorThe P/E ratio of Bio-Techne is 49.17, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 89.75.Price to Earnings Growth RatioBio-Techne has a PEG Ratio of 2.72. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBio-Techne has a P/B Ratio of 6.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Bio-Techne (NASDAQ:TECH) StockBio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics & Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. TRead More Receive TECH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter. Email Address TECH Stock News HeadlinesFebruary 5, 2023 | finance.yahoo.comBio-Techne Second Quarter 2023 Earnings: Misses ExpectationsFebruary 3, 2023 | marketwatch.com: Bio-Techne stock price target cut to $103.75 from $415.00 at Stifel NicolausFebruary 5, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! February 3, 2023 | americanbankingnews.comAnalyzing Bio-Techne (NASDAQ:TECH) and BiondVax Pharmaceuticals (NASDAQ:BVXV)February 1, 2023 | americanbankingnews.comBio-Techne (TECH) Scheduled to Post Earnings on ThursdayJanuary 31, 2023 | finance.yahoo.comBIO-TECHNE ANNOUNCES RETIREMENT, APPOINTMENT OF GENERAL COUNSELJanuary 30, 2023 | americanbankingnews.comBrokerages Set Bio-Techne Co. (NASDAQ:TECH) PT at $107.86January 28, 2023 | americanbankingnews.comStockNews.com Lowers Bio-Techne (NASDAQ:TECH) to HoldFebruary 5, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 26, 2023 | finance.yahoo.comBIO-TECHNE LAUNCHES THE MauriceFlex™ SYSTEM, ADDING cIEF FRACTIONATION CAPABILITY TO THE GOLD STANDARD MAURICE ASSAYSJanuary 17, 2023 | finance.yahoo.comBIO-TECHNE TO HOST CONFERENCE CALL ON FEBRUARY 2, 2023, TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTSJanuary 10, 2023 | finance.yahoo.comBIO-TECHNE LAUNCHES RNASCOPE PLUS ASSAY TO ADVANCE GENE THERAPY DEVELOPMENTJanuary 7, 2023 | finance.yahoo.comA Look At The Fair Value Of Bio-Techne Corporation (NASDAQ:TECH)January 2, 2023 | marketwatch.comLegal Cocaine Market Research Highlighting Global Opportunities 2023 | Growth Trends and Share Forecast to 2029December 22, 2022 | finance.yahoo.comDo You Think Bio-Techne Corporation (TECH) Has a Positive Long-Term Trend?December 21, 2022 | finance.yahoo.comBIO-TECHNE TO PRESENT AT THE 41st ANNUAL J.P. MORGAN HEALTHCARE CONFERENCEDecember 17, 2022 | finance.yahoo.comOur 7 Top Biotech Stock Picks for 2023December 7, 2022 | finance.yahoo.comBio-Techne's (NASDAQ:TECH) investors will be pleased with their impressive 160% return over the last five yearsDecember 5, 2022 | finance.yahoo.comBIO-TECHNE RELEASES MITOBRILLIANT™ FLUORESCENT DYES, PROVIDING A NEXT-GENERATION TOOL FOR IMAGING MITOCHONDRIA IN LIVE AND FIXED CELLSDecember 1, 2022 | finance.yahoo.comBio-Techne and Oxford Nanopore Technologies partner to bring innovative reproductive health and carrier screening solutions to the marketNovember 28, 2022 | finance.yahoo.comBIO-TECHNE TO PRESENT AT THE FIFTH ANNUAL EVERCORE ISI HealthCONx CONFERENCENovember 28, 2022 | finance.yahoo.comShould You Invest in Bio-Techne Corporation (TECH)?November 17, 2022 | finance.yahoo.comNAMOCELL HIGHLIGHTED IN NATURE PUBLICATION FOR EFFICIENT SINGLE CELL CLONING OF HUMAN PLURIPOTENT STEM CELLSNovember 15, 2022 | finance.yahoo.comBIO-TECHNE ANNOUNCES OPENING OF NEW IMMUNOASSAY MANUFACTURING FACILITYNovember 11, 2022 | seekingalpha.comBio-Techne: Recent Weakness, Charts Suggest It's Now A Buy (Technical Analysis)November 10, 2022 | finance.yahoo.comBIO-TECHNE TO PRESENT AT THE STEPHENS ANNUAL INVESTMENT CONFERENCENovember 8, 2022 | finance.yahoo.comBIO-TECHNE TO PRESENT AT THE STIFEL 2022 HEALTHCARE CONFERENCESee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TECH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter. Email Address TECH Company Calendar Last Earnings11/01/2021Ex-Dividend for 11/28 Dividend11/10/2022Dividend Payable11/28/2022Today2/05/2023Ex-Dividend for 2/27 Dividend2/10/2023Dividend Payable2/27/2023Next Earnings (Estimated)5/03/2023Fiscal Year End6/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryLife Sciences Tools & Services SectorMedical Current SymbolNASDAQ:TECH CUSIP87837710 CIK842023 Webwww.bio-techne.com Phone(612) 379-8854Fax612-656-4400Employees3,000Year Founded1981Price Target and Rating Average Stock Price Forecast$104.45 High Stock Price Forecast$120.00 Low Stock Price Forecast$89.00 Forecasted Upside/Downside+32.0%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$1.61 Trailing P/E Ratio49.17 Forward P/E Ratio43.49 P/E Growth2.72Net Income$272.05 million Net Margins23.38% Pretax Margin28.39% Return on Equity15.87% Return on Assets11.92% Debt Debt-to-Equity Ratio0.11 Current Ratio4.40 Quick Ratio2.92 Sales & Book Value Annual Sales$1.11 billion Price / Sales11.24 Cash Flow$2.47 per share Price / Cash Flow32.02 Book Value$11.64 per share Price / Book6.80Miscellaneous Outstanding Shares156,970,000Free Float149,985,000Market Cap$12.43 billion OptionableOptionable Beta1.21 Social Links Key ExecutivesCharles R. KummethPresident, Chief Executive Officer & DirectorJames T. HippelChief Financial OfficerBrenda Swierenga FurlowSecretary & Chief Compliance OfficerBrenda S. EversonChief Human Resources Officer & Senior VPRobert M. GavinVice President-Corporate DevelopmentKey CompetitorsQiagenNYSE:QGENNeurocrine BiosciencesNASDAQ:NBIXRepligenNASDAQ:RGENHalozyme TherapeuticsNASDAQ:HALOExelixisNASDAQ:EXELView All CompetitorsInsiders & InstitutionsIllinois Municipal Retirement FundBought 13,110 shares on 2/3/2023Ownership: 0.011%Securian Asset Management Inc.Bought 9,636 shares on 2/3/2023Ownership: 0.008%Sepio Capital LPBought 6,607 shares on 2/3/2023Ownership: 0.006%Tradition Wealth Management LLCBought 818 shares on 2/3/2023Ownership: 0.001%Ellevest Inc.Bought 306 shares on 2/3/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions TECH Stock - Frequently Asked Questions Should I buy or sell Bio-Techne stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TECH shares. View TECH analyst ratings or view top-rated stocks. What is Bio-Techne's stock price forecast for 2023? 9 brokerages have issued 1 year price objectives for Bio-Techne's stock. Their TECH share price forecasts range from $89.00 to $120.00. On average, they predict the company's share price to reach $104.45 in the next year. This suggests a possible upside of 32.0% from the stock's current price. View analysts price targets for TECH or view top-rated stocks among Wall Street analysts. How have TECH shares performed in 2023? Bio-Techne's stock was trading at $82.88 on January 1st, 2023. Since then, TECH shares have decreased by 4.5% and is now trading at $79.16. View the best growth stocks for 2023 here. When is Bio-Techne's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. View our TECH earnings forecast. How were Bio-Techne's earnings last quarter? Bio-Techne Co. (NASDAQ:TECH) posted its quarterly earnings data on Monday, November, 1st. The biotechnology company reported $0.46 earnings per share for the quarter, beating analysts' consensus estimates of $0.43 by $0.03. The biotechnology company had revenue of $257.72 million for the quarter, compared to analyst estimates of $254.37 million. Bio-Techne had a net margin of 23.38% and a trailing twelve-month return on equity of 15.87%. During the same period in the previous year, the business posted $0.29 EPS. How often does Bio-Techne pay dividends? What is the dividend yield for Bio-Techne? Bio-Techne declared a quarterly dividend on Thursday, February 2nd. Investors of record on Monday, February 13th will be paid a dividend of $0.08 per share on Monday, February 27th. This represents a $0.32 annualized dividend and a dividend yield of 0.40%. The ex-dividend date of this dividend is Friday, February 10th. This is a boost from the stock's previous quarterly dividend of $0.02. Read our dividend analysis for TECH. Is Bio-Techne a good dividend stock? Bio-Techne (NASDAQ:TECH) pays an annual dividend of $0.32 per share and currently has a dividend yield of 0.40%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 19.88%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, TECH will have a dividend payout ratio of 14.48% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for TECH. When did Bio-Techne's stock split? Bio-Techne shares split on the morning of Wednesday, November 30th 2022. The 4-1 split was announced on Tuesday, November 1st 2022. The newly issued shares were issued to shareholders after the closing bell on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split. What is Charles Kummeth's approval rating as Bio-Techne's CEO? 95 employees have rated Bio-Techne Chief Executive Officer Charles Kummeth on Glassdoor.com. Charles Kummeth has an approval rating of 73% among the company's employees. What other stocks do shareholders of Bio-Techne own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T) and Boeing (BA). What is Bio-Techne's stock symbol? Bio-Techne trades on the NASDAQ under the ticker symbol "TECH." Who are Bio-Techne's major shareholders? Bio-Techne's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (1.06%), Sumitomo Mitsui Trust Holdings Inc. (0.65%), Riverbridge Partners LLC (0.53%), New York State Common Retirement Fund (0.42%), Stephens Investment Management Group LLC (0.41%) and Artemis Investment Management LLP (0.30%). Insiders that own company stock include Alpna Seth, Brenda S Furlow, Brenda S Furlow, Charles R Kummeth, Charles R Kummeth, Glenn Hedde, Harold J Wiens, James Hippel, John L Higgins, Kim Kelderman, Norman David Eansor, Robert V Baumgartner and Roeland Nusse. View institutional ownership trends. How do I buy shares of Bio-Techne? Shares of TECH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Bio-Techne's stock price today? One share of TECH stock can currently be purchased for approximately $79.16. How much money does Bio-Techne make? Bio-Techne (NASDAQ:TECH) has a market capitalization of $12.43 billion and generates $1.11 billion in revenue each year. The biotechnology company earns $272.05 million in net income (profit) each year or $1.61 on an earnings per share basis. How many employees does Bio-Techne have? The company employs 3,000 workers across the globe. Does Bio-Techne have any subsidiaries? The following companies are subsidiares of Bio-Techne: Advanced Cell Diagnostics, Advanced Cell Diagnostics Inc., B-MoGen Biotechnologies Inc., Bio-Techne China Co. Ltd, Bio-Techne Ltd., Bionostics Inc., Cliniqa, CyVek, Exosome Diagnostics, Exosome Diagnostics Inc., MoGen Biotechnologies, Novus Biologicals, Novus Biologicals LLC, ProteinSimple, ProteinSimple Ltd., QT Holdings Corporation, Quad Technologies, Research and Diagnostic Systems Inc., Shanghai PrimeGene Bio-Tech Co. Ltd., Space Import-Export Srl, Tocris Cookson Limited, and Zephyrus Biosciences.Read More How can I contact Bio-Techne? Bio-Techne's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The official website for the company is www.bio-techne.com. The biotechnology company can be reached via phone at (612) 379-8854, via email at ir@bio-techne.com, or via fax at 612-656-4400. This page (NASDAQ:TECH) was last updated on 2/5/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.